CHEMOTHERAPY +/- ADDITIONAL CHEMOTHERAPY AND/OR XRT IN HODGKIN'S DISEASE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。（临床试验摘要来自美国国家癌症研究所的PDQ数据库）化疗中使用的药物使用不同的方法来阻止癌细胞分裂，从而使它们停止生长或死亡。以不同的组合给药可能会杀死更多的癌细胞。放射疗法使用高能x射线来破坏癌细胞。目前尚不清楚在治疗何杰金氏病时，化疗联合或不联合化疗和/或放疗是否更有效。这个随机的III期试验正在研究不同的化疗方案，包括放疗和不放疗，以比较它们在治疗新诊断的霍奇金病儿童中的效果。患者将在第1-3天和第8天接受输注或注射联合化疗。他们还将在第1-7天每天口服两到三次强的松。从第4天开始，患者还将每天注射一次非格拉西汀（第8天除外），直到血细胞计数恢复正常。治疗可以每3周重复一次，最多两个疗程。然后，患者将被分为两组。第一组患者将接受两个额外的初始化疗方案，随后进行放射治疗或不进行进一步治疗。第2组的患者将被随机分配到两组中的一组，要么接受另一种化疗方案的两个疗程加上初始化疗方案的两个额外疗程，然后进行放射治疗，要么接受初始化疗方案的两个额外疗程，然后进行放射治疗。2年内每3个月评估一次，3年内每6个月评估一次，此后每年评估一次。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease. This randomized Phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Patients will receive infusions or injections of combination chemotherapy on Days 1-3 and 8. They will also receive prednisone by mouth two or three times a day on Days 1-7. Beginning on Day 4, patients will also receive injections of filgrastim once a day (except Day 8) until blood counts return to normal. Treatment may be repeated every 3 weeks for up to two courses. Patients will then be assigned to one of two groups. Patients in Group 1 will receive two additional courses of the initial chemotherapy regimen, followed by either radiation therapy or no further treatment. Patients in Group 2 will be randomly assigned to one of two groups to receive either two courses of another chemotherapy regimen plus two additional courses of the initial chemotherapy regimen, followed by radiation therapy OR two additional courses of the initial chemotherapy regimen followed by radiation therapy. Patients will be evaluated every 3 months for 2 years, every 6 months for 3 years, and once a year thereafter.